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www.sciencedirect.comEDITORIALObesity and lung healthObesity among population has increased dramatically and has
received considerable recent public health attention. The im-
pact of obesity on lung health has become a recognized prob-
lem worldwide and an area of intense research. Obese people
are at greater risk for asthma, impaired lung mechanics,
sleep-disordered breathing, and obesity hypoventilation
syndrome.Guide to respiratory abbreviations.
Abbreviation Term Deﬁnition
AHI Apnea–hypopnea index Total number of apneas and hypopneas per hour of sleep; also see RDI
CPAP Continuous positive airway
pressure
Positive pressure delivered to the upper airway, which splints the airway open and prevents
OSA
DLCO Diﬀusion in the lung of
carbon monoxide
Part of a pulmonary function test to assess gas movement from the alveoli to the
erythrocytes, in the pulmonary capillaries. Carbon monoxide is used to make this
measurement because it mimics the behavior of oxygen
ERV Expiratory reserve volume Maximum volume of air that can be exhaled from the resting end-expiratory level
FEV1 Forced expired volume in 1 s Volume of air expired in the ﬁrst second of FVC
FRC Functional residual capacity Volume of air remaining in the lungs at end-expiration (RV+ ERV)
FVC Forced vital capacity Maximum amount of air that can be rapidly and forcefully exhaled from the lungs after full
inspiration
RDI Respiratory disturbance index Total number of events (apneas, hypopneas, and respiratory eﬀort-related arousals) per
hour of sleep; also see AHI
RV Residual volume Volume of air remaining in the lungs after maximal expiration, measured indirectly
TLC Total lung capacity Total amount of air that the lungs can hold after maximal inspiration
TV Tidal volume Amount of air that moves in and out of lungs with each breath
Adapted from C.M. Porth, Essentials of Pathophysiology, third ed., Wolters Kluwer Health/Lippincott Williams & Wilkins, Philapedia, PA,
2011.Understanding how obesity alters lung function
Alterations in the pulmonary system linked to obesity include
abnormalities in ventilatory mechanics and muscle function,
ventilatory control, pulmonary gas exchange, and cardiac per-
formance. Signs and symptoms of these problems tend to wor-
sen when an obese patient is supine [2].Peer review under responsibility of The Egyptian Society of Chest
Diseases and Tuberculosis.
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http://dx.doi.org/10.1016/j.ejcdt.2013.0Open access under CC BY-NC-ND license.Complete pulmonary function testing (measuring spirome-
try, lung volumes, and diffusion) often shows a restrictive dis-
ease pattern with decreased expiratory reserve volume (ERV)
and functional residual capacity (FRC). For more information
on pulmonary function testing, see http://www.nlm.nih.gov/
medlineplus/ency/article/003853.htm. (Also see Guide to respi-
ratory abbreviations.)Total lung capacity (TLC) and residual volume (RV) are
maintained except in cases of extreme obesity, where TLC
and RV decrease as weight increases. Most patients maintain
a normal forced expired volume in one second/forced vital
capacity ratio (FEV1/FVC) in the absence of other lung dis-
ease [2,3]. Pulmonary gas exchange (indirectly assessed by
measuring the diffusion in the lung of carbon monoxide
[DLCO]) may be normal or increased.
Obesity impairs ventilatory function in several ways. As
BMI rises, typically all lung volumes are reduced while expira-
tory airﬂow remains normal.
Mechanical effects of obesity on the diaphragm and chest
wall lead to impaired diaphragmatic excursion and reduced
thoracic compliance.he Egyptian Society of Chest Diseases and Tuberculosis.
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358 EditorialAccording to the National Heart, Lung, and Blood Insti-
tute, screening for a person’s risk of developing obesity-related
disease includes calculating the BMI, determining if other con-
ditions associated with obesity (such as a sedentary lifestyle or
hypertension) exist, and measuring waist circumference to as-
sess for abdominal fat, which predicts the risk of obesity-asso-
ciated diseases.
The risk increases for men with a waist circumference larger
than 40 inches and women with a waist circumference larger
than 35 inches [1].
Factors such as gender, race, age, and height are typically
considered when interpreting pulmonary function test results
[6]. However, these pulmonary function test results may not be
accurate indicators for obese patients because normal predicted
values for spirometry, lung volumes, and DLCO usually are not
corrected for weight [2,4]. Even though weight is not normally
considered when predicting lung values, practitioners must keep
in mind that the muscular effort required to support ventilation
at rest and during exercise is greater in a patient who is obese
than in one of normal weight. This increased muscular effort is
due mainly to the higher ventilator requirement brought on by
an increased metabolic demand and the increased mechanical
loading of the muscles used during inspiration [2].
Let us explore how obesity and decreased lung function are
associated with asthma, COPD, and sleep apnea.Classifying by BMI
Classiﬁcation BMI
Underweight <18..5
Normal 18.5–24.9
Overweight 25.0–29.9
Obesity Class 1 30.0–34.9
Obesity Class II 35.0–39.9
Extreme Obesity III P40Source: Centers for Disease Control and Prevention, Obesity
and overweight for professionals: health consequences, 2011.
http://www.cdc.gov/obesity/causes/health.html.
Obesity and asthma: Increasing together
Asthma is a chronic inﬂammatory disease that affects the air-
ways [5,6]. Most patients with asthma exhibit increased work
of breathing and decreased pulmonary function measurements
such as tidal volume (TV), ERV, FEV1, and FVC [7,8].
Rising asthma rates and poor management of the disease
are increasingly linked to obesity [7,8].
Females are more likely to have asthma than males [9]. A
small percentage of those with asthma may have gained weight
because of asthma medications (such as oral corticosteroids)
and sedentary lifestyles [7].
Obesity increases the work of breathing and probably exac-
erbates asthma symptoms caused by the inﬂammatory process
and smooth muscle contraction in the airway [7].
Breathing at low lung volumes could lead to diminished
airway stretch (or elasticity). Smooth muscle layers of the
conducting airways contain stretch receptors that are affected
by pressure changes within the airways. These receptors,
which impede inspiration and stimulate expiration, play an
essential role in establishing breathing patterns and reducingbreathing effort. They do so by making adjustments in the
TV and respiratory rate to allow for changes in airway
resistance and lung compliance. Reduced airway stretch
may create airway hyperresponsiveness, an ampliﬁed bron-
choconstrictor reaction to stimuli that have minimal to no
consequences on others [8,10].
Inﬂammatory effects
Obesity, a pro-inﬂammatory condition, increases the number
of inﬂammatory mediators and cytokines such as leptin, tumor
necrosis factor alfa (TNF-alfa), interleukin-6 (IL-6), and C-
reactive protein (CRP). Airway inﬂammation contributing to
the progression of asthma (or airway hyperresponsiveness)
may be promoted by these mediators and cytokines, which
are emitted by adipocytes. Adipocytes are fat cells in adipose
tissue (body fat) that have a cellular volume consisting mostly
of pure triglycerides [2]. Upper body (visceral, central, or
abdominal) obesity is the main contributing factor in the
chronic inﬂammatory response seen in people who are obese
[6]. (See Comparing apples and pears.)
Leptin is a protein released by adipocytes that suppresses
the appetite by signaling the sensation of satiety and raises en-
ergy expenditure. It is also a pro-inﬂammatory hormone that is
greatly increased in obese people with asthma, which stimu-
lates the release of the inﬂammatory cytokines IL-6 and
TNF-alfa [6,7]. IL-6, the chief mediator in acute phase re-
sponse, leads to the production of CRP, which intensiﬁes the
inﬂammatory response. IL-6 and TNF-alfa are associated with
increased IgE production, subepithelial ﬁbrosis, and remodel-
ing of the airways, the primary pathogenesis of asthma [6].
In a recent study of the relationship of inﬂammatory cyto-
kines of asthma and obesity, Canoz et al., found a positive cor-
relation between biochemical markers (such as erythrocyte
sedimentation rate [ESR], CRP, TNF-alfa, and IL-6 levels)
and parameters of obesity such as BMI, waist circumference,
and waist-to-hip ratio [6].
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The primary goal of asthma treatment is to satisfactorily con-
trol the disease to achieve optimal pulmonary function, mini-
mal daytime symptoms and use of rescue bronchodilators,
normal activities of daily living, absence of nighttime symp-
toms, and only mild and infrequent exacerbations. Most pa-
tients can achieve satisfactory control with individualized
drug therapy, asthma education, environmental control mea-
sures, and appropriate follow-up.
Asthma may be more difﬁcult to control in patients who are
obese. This difﬁculty may be associated with factors such as
obesity-induced airway changes (for instance, increased airway
inﬂammation and smooth muscle contraction), diminished
responsiveness to some medications (such as inhaled cortico-
steroids and long-acting steroids), or the impact of obesity re-
lated comorbid conditions (such as obstructive sleep apnea and
gastroesophageal reﬂux disease [GERD]) [7].
Other associated factors may include the hormonal effects
of increased estrogen in females who are obese (it may interfere
with the immune response) and worsening of asthma symp-
toms in obese people with asthma that is linked to theophylline
use (which may contribute to GERD by decreasing lower
esophageal sphincter tone) [4,8]. Tailored pharmacotherapy
is an important management consideration in these patients.
Obesity, smoking, and physical inactivity are modiﬁable
risk factors that can cause or exacerbate asthma [9]. Smoking
is also associated with a decreased response to corticosteroids
[9].
The key to weight loss is to balance the energy intake with
energy expenditure [7]. Exercise training is an effective and
safe way for those with asthma to improve ﬁtness and exer-
cise performance. Walking (following U.S. physical activity
guidelines) is appropriate even for those with severe asthma
[11].
The most dramatic improvements in asthma symptoms oc-
cur in morbidly obese patients who have undergone bariatric
surgery [7]. Bariatric surgery is typically reserved for severely
obese people who are not able to lose weight [12]. These pa-
tients, as a result of ineffective nutrient absorption and early
satiety produced by intestinal bypass and/or gastric restriction,
respectively, loose a signiﬁcant amount of weight within the
ﬁrst 12 to 18 months after the procedure [13]. Even modest
amounts of weight loss are associated with improved asthma
severity and control [7].
To further manage symptoms, instruct a patient with asth-
ma to be aware of exercise-induced asthma as physical activity
increases and to avoid triggers such as pollen, dust, dust mites,
cats, fumes, changes in temperature, and smoke [14].
Obesity and COPD: Raising the risks
COPD, which includes emphysema and chronic bronchitis, is
associated with an abnormal inﬂammatory response of the
lungs due to noxious stimuli. These diseases have many com-
mon signs and symptoms, such as shortness of breath, cough,
exercise intolerance, and airﬂow limitation that is not com-
pletely reversible [15].
The population of patients with COPD is growing as fast as
the population of those with obesity [5]. Both conditions are
major causes of mortality and morbidity.Abdominal obesity is about twice as prevalent in patients
diagnosed with COPD [2]. The long-term effects of obesity,
such as low-grade systemic inﬂammation and insulin resis-
tance, could also contribute to increased cardiovascular dis-
ease and mortality [2].
Most patients with COPD exhibit a nonreversible decrease
in FEV1 and FVC (both values are less than 80% of predicted
values) along with an FEV1/FVC ratio of less than 70%.
Unlike patients with asthma who have improved lung func-
tion with treatment, airﬂow limitation persists in patients with
COPD [4]. The work of breathing and oxygen demand are in-
creased whether these patients are at rest or exercising. With
exercise and increased ventilator requirements, these patients
may have expiratory ﬂow limitations that can lead to consider-
able air trapping and an increased end-expiratory lung volume,
as reﬂected in the FRC measurement. Restrictive deﬁcits com-
bined with airﬂow limitation result in increased shortness of
breath and exercise limitations.
In the early stages of COPD, visceral obesity has an espe-
cially negative impact on exercise performance [3]. Seres
et al. (as reported by Ramachandran et al.) found that dimin-
ished exercise ability in patients who were morbidly obese was
linked to increases in oxygen requirements, systolic BP, and
heart rate. The researchers theorized that these patients with
larger body masses required additional energy to create motion
due to their diminished exercise ability [3].Management of COPD
Weight loss is the best health strategy for obese patients with
COPD. Cardiac risk factors such as hypertension, diabetes,
dyslipidemia, and obesity should be evaluated and managed
according to current evidence-based guidelines [3]. Adding pul-
monary rehabilitation and exercise training may increase the
effectiveness of weight-loss plans and reduce cardiac risk fac-
tors [5].
Common therapeutic recommendations include using bron-
chodilators, supplemental oxygen, inhaled or systemic cortico-
steroids, antibiotics, and methylxanthines (theophylline) as
indicated [16].
 Short-acting bronchodilators such as albuterol and short-
or long-acting anticholinergics such as ipratropium or tiot-
ropium are prescribed to relax smooth muscles and improve
symptoms.
 Oxygen should be considered for obese patients with hyp-
oxic COPD, as well as those with type 2 diabetes and insulin
resistance, because supplemental oxygen increases insulin
sensitivity and glucose tolerance [2].
According to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines, oxygen therapy should be
initiated for patients with stage IV COPD. Patients categorized
as stage IV have very severe COPD (FEV1/FVC less than 0.70
and FEV1 less than 30% of predicted values, or FEV1 less
than 50% of predicted values with chronic respiratory failure).
The GOLD guidelines give the goal for oxygen therapy
(resting PaO2 of at least 60 mmHg and/or SaO2 greater than
90% at sea level). According to the GOLD guidelines, the indi-
cations for oxygen therapy fall into two categories: ﬁrst, for
those who have a PaO2 of 55 mmHg or less or SaO2 of 88%
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45 mmHg); second, for those who have a PaO2 55 to 60 mmHg
or SaO2 of 88% and show evidence of pulmonary hyperten-
sion, pulmonary edema (which suggests heart failure), or a
hematocrit greater than 55% [18].
 Inhaled corticosteroids should be given for patients with
stage III or IV COPD (severe or very severe) if they are hav-
ing repeated exacerbations in order to reduce the frequency
of exacerbations and reduce airway inﬂammation (Systemic
corticosteroids are recommended only for short-term treat-
ment of exacerbations but not on a long-term basis) [16].
 Antibiotics are useful for patients with COPD who are
experiencing infectious exacerbations and/or other bacterial
infections, but they should not be used as prophylactic ther-
apy [16].
 Methylxanthines (such as theophylline) have been shown to
be effective in COPD as bronchodilators, but due to their
adverse reactions and potential toxicity, inhaled bronchod-
ilators are preferred to treat bronchospasm [16]
Besides helping to establish the COPDdiagnosis, pulmonary
function tests can help assess the patient’s response to treatment.
A patient with ventilatory failure may need continuous positive
airway pressure (CPAP) or endotracheal intubation.
Obesity and obstructive sleep apnea: Common bedfellows
Sleep apnea is deﬁned as the cessation of airﬂow for at least
10 s corresponding with an arousal from sleep or oxyhemoglo-
bin desaturation [12].
Obstructive sleep apnea (OSA) is characterized by contin-
uing respiratory effort in the face of an absence or serious
impairment of airﬂow. OSA is caused by recurring episodes
of upper airway obstruction, usually by the tongue and pha-
ryngeal tissues. During sleep, the muscles of the upper airway
relax and the airway opening tends to collapse. As the dia-
phragm contracts and moves downward to generate negative
pressure in the lower airways to inspire air, the upper airway
collapses as the tissues and the tongue are sucked into the air-
way opening. At a minimum, this causes snoring, but it may
also cause decreased movement of air (hypopnea) and/or air-
way obstruction resulting in apnea [17].
The patient is asleep, unaware of this series of events related
to breathing, and respiratory efforts continue, although air-
ﬂow is dramatically reduced or completely stopped.
Hypoxemia and hypercapnia develop, and eventually the
patient’s sleep moves from a lower level or stage to a higher le-
vel (arousal). With this change in brain activity (as measured
by electroencephalography), breathing resumes. The hypox-
emia and hypercapnia reverse as airﬂow restarts, but soon
the cycle begins again. This pattern recurs throughout the sleep
time. Sleep is disrupted by these frequent arousals [20]. Ana-
tomic alterations in people who are obese increase the risk of
airway collapse during sleep [15,19].
Risk factors for OSA include obesity, abnormalities in the
upper airway and facial structures, and problems related to
the soft tissues in the upper airway (such as enlarged tonsils,
tongue, or uvula). Potential risk factors for OSA include
heredity, smoking, nasal congestion, and diabetes [4]. Signiﬁ-
cant OSA exists in about 40% of people who are obese, andabout 70% of those with OSA are obese. Increased body
weight is associated with increased collapsibility of airways
in OSA [18].
The total number of apneas and hypopneas per hour of
sleep is generally reported as the apnea–hypopnea index
(AHI), which is the major index of sleep apnea severity, or
the respiratory disturbance index (RDI). OSA is deﬁned as:
 ‘‘More than 15 apneas, hypopneas, or respiratory effort–
related arousals (RERAs) per hour of sleep (that is, an
AHI or RDI greater than 15 events per hour) in an asymp-
tomatic patient, OR.
 ‘‘More than ﬁve apneas, hypopneas, or RERAs per hour of
sleep (that is, an AHI or RDI greater than 5 events per
hour) in a patient with symptoms (such as sleepiness, fati-
gue, and inattention) or signs of disturbed sleep (such as
snoring, restless sleep, and respiratory pauses). More than
75% of the apneas or hypopneas must have an obstructive
pattern’’ [4].
The consequences of OSA include a host of problems. Fre-
quent interruptions in quality sleep time lead to excessive day-
time sleepiness and loss of cognitive function. These patients
face an increased risk of severe arterial hypoxemia, higher sym-
pathetic tone, systemic and pulmonary hypertension, cardiac
dysrhythmias, heart failure, chronic snoring, cardiovascular
disease, and strokes [12,19].
Severe OSA (deﬁned as an AHI greater than 30) carries a
three- to sixfold increased risk in all-cause mortality compared
to normal people.
Patients with OSA also have more motor vehicle crashes,
which are caused when they fall asleep while driving. They
are also at higher risk for perioperative problems, such as dif-
ﬁcult endotracheal intubation and longer anesthesia recovery
time [4].
Although obesity ampliﬁes the risk of OSA, OSA can also
promote weight gain and obesity. Studies have shown that
many patients newly diagnosed with OSA have recently gained
excessive weight.
Management of OSA
The goal of treatment in OSA is to decrease the severity of
respiratory events associated with sleep arousal and oxyhemo-
globin desaturation [18,19]. CPAP, the treatment of choice for
obese patients with OSA, may lower BP and improve endothe-
lial function [5,18]. For a patient with OSA who needs a CPAP
mask, ensure that it ﬁts properly.
Evidence supports medical and surgical treatment for
weight loss to improve OSA. If weight loss efforts fail, bariat-
ric surgery should be considered [5,13,19]. Bariatric surgery
has been shown to reduce patients’ BMI by around 15 kg/m2
and reduces their AHI by 36 events per hour. This suggests
that every reduction in BMI of 1 unit is linked to a reduction
in the AHI of 2.3 units [20].
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